Teijin (3401) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 Aug, 2025Executive summary
Adjusted operating income for FY2025 1Q was ¥7.8 billion, down ¥2.6 billion year-over-year, mainly due to large-scale periodic maintenance in the Materials Business and structural reform expenses in aramid.
Revenue for Q1 FY2025 was ¥243.1 billion, down ¥12.2 billion or 4.8% year-over-year.
Net loss attributable to owners was ¥740 million, compared to a profit of ¥4,451 million in the prior year.
The transfer of the North American composites business was completed July 1, 2025, with related losses already factored into the outlook.
Comprehensive income dropped to ¥5,438 million from ¥20,358 million year-over-year.
Financial highlights
EBITDA for FY2025 1Q was ¥23.2 billion, down ¥6.2 billion year-over-year; adjusted operating income margin declined to 3.2%.
Operating income declined sharply to ¥2,295 million from ¥8,041 million.
Free cash flow improved to -¥1.9 billion from -¥8.4 billion year-over-year, with operating cash flow up by ¥8.0 billion.
Net cash provided by operating activities increased to ¥16,622 million from ¥8,631 million.
Net cash provided by financing activities surged to ¥97,769 million from ¥44,364 million.
Outlook and guidance
FY2025 adjusted operating income is forecast at ¥35.0 billion, up ¥7.4 billion from FY2024, with revenue expected to decrease by ¥145.5 billion due to the composites business withdrawal.
Annual dividend forecast remains at 50 yen per share; no change from previous outlook.
Profit attributable to owners of parent is projected at ¥12.0 billion, down ¥16.3 billion year-over-year.
Latest events from Teijin
- Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation27 Feb 2026 - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 202623 Feb 2026 - Profit and revenue growth offset healthcare headwinds, with rare disease and home care focus.3401
Q3 202523 Dec 2025 - Growth centers on high-value, sustainable solutions and global market expansion.3401
Investor Day 202519 Dec 2025 - Major impairment and business transfer drive net loss; outlook cut, dividend steady.3401
Q2 20261 Dec 2025 - FY2024 saw profit recovery and portfolio transformation; higher FY2025 income expected.3401
Q4 202520 Nov 2025 - Teijin accelerates healthcare growth with a focus on rare diseases, home care, and innovation.3401
Investor Update13 Jun 2025 - Q1 FY2024 revenue and profit surged, with IT business divestiture and IFRS adoption underway.3401
Q1 202513 Jun 2025 - Impairment losses offset strong 1H growth; asset sales and restructuring support FY2024 outlook.3401
Q2 202513 Jun 2025